70S ribosome · PROTEIN NUCLEIC-ACID COMPLEX · Staphylococcus aureus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-1470S ribosome shows approved-linked disease relevance led by impetigo. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q2FW31. Start with impetigo, then reuse UniProt Q2FW31 as the stable protein anchor across project notes and exports.
Start with impetigo, then reuse UniProt Q2FW31 as the stable protein anchor across project notes and exports.
70S ribosome shows approved-linked disease relevance led by impetigo. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with impetigo because it currently carries approved-linked support. Linked drugs include RETAPAMULIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySmall ribosomal subunit protein uS11
Review this target as 70S ribosome, mapped to UniProt Q2FW31. ChEMBL maps the protein component as Small ribosomal subunit protein uS11. Sequence length is 129 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 70S ribosome as ChEMBL target CHEMBL2364096, mapped to UniProt Q2FW31. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 70S ribosome is the right protein anchor across sources, using UniProt Q2FW31 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why impetigo is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 70S ribosome |
| Target Type | PROTEIN NUCLEIC-ACID COMPLEX |
| Organism | Staphylococcus aureus |
| UniProt | Q2FW31 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Small ribosomal subunit protein uS11 |
| UniProt Accession | Q2FW31 |
| Component Type | Protein |
| Sequence Length | 129 aa |
Small ribosomal subunit protein uS11
Review this target as 70S ribosome, mapped to UniProt Q2FW31. ChEMBL maps the protein component as Small ribosomal subunit protein uS11. Sequence length is 129 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
70S ribosome shows approved-linked disease relevance led by impetigo. 3 more disease programs remain visible in the same review block.
Start review with impetigo because it currently carries approved-linked support. Linked drugs include RETAPAMULIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.